Ewing Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Ewing Sarcoma Marketed and Pipeline Drugs Report Overview
Ewing sarcoma (ES) is an aggressive tumor of adolescents and young adults that constitutes 10% to 15% of all bone sarcomas. The disease is named after James Ewing, who first described it in 1921. These sarcomas originate from unique mesenchymal progenitor cells due to their similar histologic and immunohistochemical characteristics. The most common anatomical sites include the pelvis, axial skeleton, and femur; however, it may occur in almost any bone or soft tissue. Typically, patients present with pain and swelling over the site of involvement.
Key Mechanism of Action (Marketed Drugs) |
|
Key Routes of Administration (Marketed) |
|
Key Molecule Types (Marketed) | · Small Molecules |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Key Mechanisms of Action (Pipeline Drugs) |
|
Key Routes of Administration |
|
Key Molecule Types |
|
Top Sponsors (Marketed and Pipeline Drugs) |
|
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
The Ewing Sarcoma marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for Ewing Sarcoma. The report also analyzes the clinical and commercial landscapes of Ewing Sarcoma, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
Ewing Sarcoma Marketed Drugs Segmentation by Mechanism of Action
The key routes of administration for Ewing Sarcoma marketed drugs are genes, nucleic acids & related components inhibitors, enzyme inhibitors, and protein and peptide inhibitors. In 2023, the mostly used mechanism of action for the Ewing Sarcoma marketed drugs market is the genes, nucleic acids & related components inhibitor.
Ewing Sarcoma Marketed Drugs Analysis by MoA, 2023 (%)
For more MoA insights into the Ewing Sarcoma marketed drugs, download a free report sample
Ewing Sarcoma Marketed Drugs Segmentation by Routes of Administration
In 2023, most of the marketed drugs for Ewing Sarcoma follow the injection RoA, followed by the oral RoA.
Ewing Sarcoma Marketed Drugs Analysis by RoA, 2023 (%)
For more RoA insights into the Ewing Sarcoma marketed drugs market, download a free report sample
Ewing Sarcoma Pipeline Drugs Segmentation by Mechanisms of Action
The key mechanisms of action for Ewing Sarcoma pipeline drugs are enzyme inhibitor, cytotoxic, protein and peptide inhibitor, receptor inhibitor, receptor antagonist, receptor agonist, and enzyme activator among others. In 2023, most of the Ewing Sarcoma pipeline drugs followed the enzyme inhibitor MoA.
Ewing Sarcoma Pipeline Drugs Analysis by MoA, 2023 (%)
For more MoA insights into the Ewing Sarcoma pipeline drugs market, download a free report sample
Ewing Sarcoma Pipeline Drugs Segmentation by Routes of Administration
The key routes of administration for Ewing Sarcoma pipeline drugs are injection, topical, oral, and inhalational. In 2023, for all the Ewing Sarcoma pipeline drugs, injection is the most common route of administration, followed by oral therapies.
Ewing Sarcoma Pipeline Drugs Analysis by RoA, 2023 (%)
For more RoA insights into the Ewing Sarcoma pipeline drugs market, download a free report sample
Ewing Sarcoma Pipeline Drugs Segmentation by Molecule Type
The key molecule types for the Ewing Sarcoma drugs market are biologics, small molecules, and oligonucleotide. In 2023, the Ewing Sarcoma pipeline is mostly made up of small molecules.
Ewing Sarcoma Pipeline Drugs Analysis by Molecule Types, 2023 (%)
For more molecule type insights into the Ewing Sarcoma pipeline drugs market, download a free report sample
Top Sponsors in the Ewing Sarcoma Marketed and Pipeline Drugs Market
Some of the top sponsors in the Ewing Sarcoma marketed and pipeline drugs market are the National Cancer Institute US, Children’s Oncology Group, Pharma Mar SA, Elsai Co Ltd, Gradalis Inc, Incyte Corp, Bristol-Myers Squibb Co, and Emory University among others. In 2023, academic sponsors dominated the clinical trials space in ES over the past 10 years with National Cancer Institute US sponsoring the highest number of clinical trials overall.
Ewing Sarcoma Pipeline Drugs Analysis by Top Sponsors, 2023 (%)
For more sponsor-related insights into the Ewing Sarcoma pipeline drugs market, download a free report sample
Segments Covered in the Report
Ewing Sarcoma Marketed Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Injection
- Oral
Ewing Sarcoma Marketed Drugs Mechanism of Action Outlook (Number of Drugs, 2023)
- Genes, Nucleic Acids & Related Components Inhibitors
- Enzyme Inhibitors
- Protein and Peptide Inhibitors
Ewing Sarcoma Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Enzyme Inhibitor
- Cytotoxic
- Protein and Peptide Inhibitor
- Receptor Inhibitor
- Receptor Antagonist
- Others
Ewing Sarcoma Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Topical
- Oral
- Injection
- Inhalational
Ewing Sarcoma Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Small Molecule
- Biologic
- Oligonucleotide
Scope
GlobalData’s Ewing Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Ewing Sarcoma market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Ewing Sarcoma market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which RoA for Ewing Sarcoma marketed drugs has the highest share?
In 2023, the most marketed drugs for Ewing Sarcoma use the injection RoA.
-
Which MoA for Ewing Sarcoma marketed drugs has the highest share?
In 2023, most of the marketed drugs for Ewing Sarcoma adopt the genes, nucleic acids & related components inhibitors MoA.
-
Which MoA for Ewing Sarcoma pipeline drugs holds the largest share?
In 2023, most of the Ewing Sarcoma pipeline drugs are enzyme inhibitor.
-
Which RoA for Ewing Sarcoma pipeline drugs accounts for the highest share?
In 2023, for all the Ewing Sarcoma pipeline drugs, injection is the most common route of administration.
-
Which molecule type for Ewing Sarcoma pipeline drugs has the highest share?
In 2023, most of the pipeline drugs for Ewing Sarcoma are small molecule.
-
Who are the top sponsors for Ewing Sarcoma marketed and pipeline drugs market?
Some of the top sponsors in the Ewing Sarcoma marketed and pipeline drugs market are the National Cancer Institute US, Children’s Oncology Group, Pharma Mar SA, Elsai Co Ltd, Gradalis Inc, Incyte Corp, Bristol-Myers Squibb Co, and Emory University among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.